Navigation Links
Exosome Diagnostics Appoints Former Roche Executive Greg Zdechlik as Chief Operating Officer
Date:7/23/2009

Zdechlik was Founding member of the U.S. Clinical Molecular Diagnostic Group

NEW YORK, July 23 /PRNewswire-USNewswire/ -- Exosome Diagnostics, Inc., the developer of non-invasive molecular oncology diagnostics to aid in early cancer detection and therapeutic selection, announced today that Greg Zdechlik has been named Chief Operating Officer. As COO, Zdechlik will be responsible for driving diagnostic development, commercial relations, and product introduction including Exosome's new blood based EGFR, KRAS and BRAF assays.

"Greg brings considerable industry expertise to our operating team," said James McCullough, Chief Executive Officer of Exosome Diagnostics. "His track record of developing and growing platform technologies, including Roche's highly successful PCR products, will help us navigate licensing and production of exosome non-invasive oncology assay."

Mr. Zdechlik, an in-vitro diagnostic industry veteran, has been with Roche Diagnostics for over 22 years, including 15 years in the clinical molecular diagnostics field. He served as a founding commercial team member of Roche Diagnostic's U.S. clinical molecular diagnostics group and has held executive level positions including sales management, corporate development and strategic marketing. His responsibilities included leading the effort to seek new technologies, evaluating new business opportunities for the U.S. diagnostic business, developing strategic investment and action plans to achieve U.S. market leadership for key Roche business platforms, directing efforts to ensure that clinical endpoints, clinical trial design, publication strategy, market development strategy, key opinion leader development and health economic strategy for high value technologies were aligned with the market needs to achieve peak product sales faster.

"This is one of the more exciting technologies I have seen in molecular diagnostics," said Zdechlik. "Exosome's technology has the potential to enable a series of companion and tumor profiling diagnostics which deliver valuable information for clinicians to precisely monitor cancer status and manage available therapies."

About Exosome Diagnostics

Exosome Diagnostics is a developer of proprietary molecular diagnostic tests with applications in oncology and metabolic disease. The company's core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers that can be reliably harvested from blood and urine and used diagnostically. For more information, visit www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Exosome Diagnostics Announces Additions to Management Team
2. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
3. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Strategic Diagnostics Updates Roth Conference Presentation Time
6. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
9. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
10. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
11. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... From industry leaders, sports stars, and Hollywood icons to thousands of everyday, ... had lost all hope. Their stories are told here. , Chapter 13: ... “Neil takes readers on a riveting journey through the past, present and future of ...
(Date:9/20/2017)... ... September 20, 2017 , ... RoviSys, a leading ... today the opening of an office in Taipei, Taiwan. This new location allows ... while developing new relationships in the region. Located in the Neihu area of ...
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this educational ... fume hood. Along with the advantages and disadvantages of ductless, filtered fume hoods, ... in the laboratory. , Attendees will learn from an industry expert about the ...
(Date:9/19/2017)... ... 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is ... "Stem Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan met in 2003 ... interest in the potential of stem cell therapy and a fast friendship was formed. , ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):